NCT00356421 - A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

Inhaled Human Insulin (Exubera®)

Preprandial inhaled insulin regimen and administration of insulin glargine QD

DRUG

Insulin lispro (Humalog)

Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.

Trial Locations (23)

2650

Pfizer Investigational Site, Edegem

3000

Pfizer Investigational Site, Leuven

3600

Pfizer Investigational Site, Genk

4095

Pfizer Investigational Site, Stavanger

8000

Pfizer Investigational Site, Aarhus

29609

Pfizer Investigational Site, Brest

35016

Pfizer Investigational Site, Las Palmas

46010

Pfizer Investigational Site, Valencia

67091

Pfizer Investigational Site, Strasbourg

70211

Pfizer Investigational Site, Kuopio

91106

Pfizer Investigational Site, Corbeil-Essonnes

08610

Pfizer Investigational Site, Hamilton

08903

Pfizer Investigational Site, New Brunswick

A-1030

Pfizer Investigational Site, Vienna

A-1130

Pfizer Investigational Site, Vienna

Unknown

Pfizer Investigational Site, Waterford

NL-1105 AZ

Pfizer Investigational Site, Amsterdam

1349-019

Pfizer Investigational Site, Lisbon

171 76

Pfizer Investigational Site, Stockholm

182 88

Pfizer Investigational Site, Stockholm

BH7 7DW

Pfizer Investigational Site, Bournemouth

DD1 9SY

Pfizer Investigational Site, Dundee

B9 5SS

Pfizer Investigational Site, Birmingham